Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Marco Galluzzo, Marina Talamonti, Laura Atzori, Federico Bardazzi, Anna Campanati, Antonella Di Cesare, Federico Diotallevi, Maria Laura Flori, Cristina Mugheddu, Annamaria Offidani, Stefano Piaserico, Filomena Russo, Lidia Sacchelli, Luca Bianchi & Francesca Prignano. (2022) Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opinion on Biological Therapy 22:4, pages 547-554.
Read now
Read now
M Galluzzo, G Caldarola, C De Simone, N Bernardini, G Moretta, S Pallotta, E Botti, E Campione, F Pirro, C. Potenza, L Bianchi & K Peris. (2021) Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opinion on Biological Therapy 21:9, pages 1299-1310.
Read now
Read now
M. Galluzzo, S. D’Adamio, D. Silvaggio, P. Lombardo, A. Massaro, C. G. Egan, L. Bianchi & M. Talamonti. (2020) Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opinion on Biological Therapy 20:1, pages 95-104.
Read now
Read now
Patrizia Alvisi, Serena Arrigo, Salvatore Cucchiara, Paolo Lionetti, Erasmo Miele, Claudio Romano, Alberto Ravelli, Daniela Knafelz, Stefano Martelossi, Graziella Guariso, Salvatore Accomando, Giovanna Zuin, Costantino De Giacomo, Lucio Balzani, Monia Gennari & Marina Aloi. (2019) Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics: Targets and Therapy 13, pages 13-21.
Read now
Read now
Raphaël Lijnen, Elsemieke Otters, Deepak Balak & Bing Thio. (2016) Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study. Journal of Dermatological Treatment 27:1, pages 31-36.
Read now
Read now
Articles from other publishers (29)
Alexandre Persu, Maria S Stoenoiu, Frédéric Maes, Reinhold Kreutz, Giuseppe Mancia & Sverre E Kjeldsen. (2023) Late outcomes of renal denervation are more favourable than early ones: facts or fancies?. Clinical Kidney Journal 16:12, pages 2357-2364.
Crossref
Crossref
Jonathan I. Silverberg, April Armstrong, Andrew Blauvelt & Kristian Reich. (2023) Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids. American Journal of Clinical Dermatology 24:6, pages 913-925.
Crossref
Crossref
Kristian Reich, Jonathan I. Silverberg, Kim A. Papp, Mette Deleuran, Norito Katoh, Bruce Strober, Lisa A. Beck, Marjolein de Bruin‐Weller, Thomas Werfel, Fan Zhang, Pinaki Biswas, Marco D. DiBonaventura, Gary Chan, Susan Johnson, Saleem A. Farooqui, Urs Kerkmann & Claire Clibborn. (2023) Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Jad El Masri, Ahmad Afyouni, Maya Ghazi, Tarek Baroud, Doha Al Majdalany, Aalaa Saleh, Hadi El Assaad & Pascale Salameh. (2023) Current state of clinical trials on xenograft. Xenotransplantation 30:3.
Crossref
Crossref
Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon & Yoon Jun Kim. (2023) Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study. Journal of Korean Medical Science 38:28.
Crossref
Crossref
Elvira Fanelli & Alexandre Persu. (2022) SYMPLICITY HTN-3: failure at 6 months, success at 3 years?. The Lancet 400:10361, pages 1382-1383.
Crossref
Crossref
Deepak L Bhatt, Muthiah Vaduganathan, David E Kandzari, Martin B Leon, Krishna Rocha-Singh, Raymond R Townsend, Barry T Katzen, Suzanne Oparil, Sandeep Brar, Vanessa DeBruin, Martin Fahy, George L Bakris, Deepak L Bhatt, George Bakris, Sidney A Cohen, Ralph D'Agostino, Murray Esler, John Flack, David E Kandzari, Barry Katzen, Martin Leon, Laura Mauri, Manuela Negoita, Suzanne Oparil, Krishna Rocha-Singh, Ray Townsend, Ziad Abbud, Tayo Addo, David Anderson, John Angle, Herbert Aronow, Anvar Babaev, Keith Benzuly, Somjot Brar, David Brown, David Calhoun, Paul Casale, Sheldon Chaffer, James Choi, Eugene Chung, Debbie L Cohen, Mark Creager, George Dangas, Harold Dauerman, Shukri David, Mark Davies, Eduardo de Marchena, Ali E Denktas, Chandan Devireddy, William Downey, Mark Dunlap, Daniel Fisher, John Flack, Magdi Ghali, Eric Gnall, Raghava Gollapudi, Mark Goodwin, Nilesh Goswami, Luis Gruberg, Rajiv Gulati, Anuj Gupta, Anjan Gupta, Hitinder Gurm, Jeffrey Hastings, Scott Kinlay, Robert Kipperman, Maurice Buchbinder, Ajay Kirtane, Richard Kovach, David Lee, Samuel Mann, Steven Marso, Fadi Matar, Ernest Mazzaferri, Farrel Mandelsohn, Issam Moussa, Timothy Murphy, Sandeep Nathan, Brian Negus, Sahil Parikh, Manesh Patel, Kirikumar Patel, Basil Paulus, George Petrossian, Alex Powell, Jacek Preibisz, Florian Rader, Otelio Randall, Mahmood Razavi, John Reilly, Jonathan Reiner, Michael Ring, Mark Robbins, Kevin Rogers, Nicolas Ruggiero, Renato Santos, William Little, John Schindler, Thomas Scott, Thomas Shimshak, Mehdi Shishehbor, Mitchel Silver, Jasvindar Singh, Kanwar Singh, David Slovut, Rick G Stoufer, Paul Teirsten, Thomas Todoran, George Vetrovec, Ron Waksman, Yale Wang, Sergio Waxman, Robert Wilkins, Khaled Ziada & Frank Zidar. (2022) Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. The Lancet 400:10361, pages 1405-1416.
Crossref
Crossref
Gangadhar Hari, Anoop Kishore & Sreedhara Ranganath Pai Karkala. (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?. European Journal of Pharmacology 929, pages 175147.
Crossref
Crossref
Viktoria Bergqvist, Johanna Holmgren, Daniel Klintman & Jan Marsal. (2022) Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 55:11, pages 1389-1401.
Crossref
Crossref
Shruti Chandra. (2021) Response to: Comment on: Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye 36:2, pages 474-474.
Crossref
Crossref
Jonathan I. Silverberg, Eric L. Simpson, April W. Armstrong, Marjolein S. de Bruin-Weller, Alan D. Irvine & Kristian Reich. (2021) Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology 23:1, pages 1-11.
Crossref
Crossref
C.G. Purvis, V.K. Emmerich & S.R. Feldman. (2021) Tildrakizumab: interpreting the data. British Journal of Dermatology 185:2, pages 242-243.
Crossref
Crossref
Catharina von Stülpnagel, Matthias Augustin & Rachel Sommer. (2021) Daten kritisch bewerten können. Der Deutsche Dermatologe 69:3, pages 228-237.
Crossref
Crossref
Jingjing Chen, Sharon Hunter, Krisztina Kisfalvi & Richard A. Lirio. (2021) A hybrid approach of handling missing data under different missing data mechanisms: VISIBLE 1 and VARSITY trials for ulcerative colitis. Contemporary Clinical Trials 100, pages 106226.
Crossref
Crossref
Agnieszka Lemanska, Karen Poole, Bruce A Griffin, Ralph Manders, John M Saxton, Lauren Turner, Joe Wainwright & Sara Faithfull. (2019) Community pharmacy lifestyle intervention to increase physical activity and improve cardiovascular health of men with prostate cancer: a phase II feasibility study. BMJ Open 9:6, pages e025114.
Crossref
Crossref
Kunlawat Thadanipon, Thunyarat Anothaisintawee, Sasivimol Rattanasiri, Ammarin Thakkinstian & John Attia. (2019) Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology 80:5, pages 1435-1444.
Crossref
Crossref
Brona Wynne, Louise McHugh, Wei Gao, Denise Keegan, Kathryn Byrne, Catherine Rowan, Karen Hartery, Clemens Kirschbaum, Glen Doherty, Garret Cullen, Barbara Dooley & Hugh E. Mulcahy. (2019) Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. Gastroenterology 156:4, pages 935-945.e1.
Crossref
Crossref
M. Talamonti, M. Galluzzo, N. Bernardini, G. Caldarola, S. Persechino, F. Cantoresi, C.G. Egan, C. Potenza, K. Peris & L. Bianchi. (2018)
Psoriasis Area and Severity Index response in moderate‐severe psoriatic patients switched to adalimumab: results from the
OPPSA
study
. Journal of the European Academy of Dermatology and Venereology 32:10, pages 1737-1744.
Crossref
Crossref
L.A.A. Gerbens, S.A.S Hamann, M.W.D. Brouwer, E. Roekevisch, M.M.G. Leeflang & P.I. Spuls. (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. British Journal of Dermatology 178:6, pages 1288-1296.
Crossref
Crossref
Viktoria Bergqvist, Mohammad Kadivar, Daniel Molin, Leif Angelison, Per Hammarlund, Marie Olin, Jörgen Torp, Olof Grip, Stefan Nilson, Erik Hertervig, Jan Lillienau & Jan Marsal. (2018) Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology 11, pages 175628481880124.
Crossref
Crossref
Seong Hoon Kim, Sung Chul Lim, Jiyeon Kim, Byung-Chul Son, Kyung Jin Lee & Young-Min Shon. (2017) Long-term follow-up of anterior thalamic deep brain stimulation in epilepsy: A 11-year, single center experience. Seizure 52, pages 154-161.
Crossref
Crossref
Thomas Bardin, Robert T Keenan, Puja P Khanna, Jeff Kopicko, Maple Fung, Nihar Bhakta, Scott Adler, Chris Storgard, Scott Baumgartner & Alexander So. (2017) Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases 76:5, pages 811-820.
Crossref
Crossref
Kenneth G. Saag, David Fitz‐Patrick, Jeff Kopicko, Maple Fung, Nihar Bhakta, Scott Adler, Chris Storgard, Scott Baumgartner & Michael A. Becker. (2016) Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study). Arthritis & Rheumatology 69:1, pages 203-212.
Crossref
Crossref
Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Shintaro Hirata, Shunsuke Fukuyo, Ippei Miyagawa, Kentaro Hanami, Kazuyoshi Saito & Yoshiya Tanaka. (2016) Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Annals of the Rheumatic Diseases 75:7, pages 1321-1327.
Crossref
Crossref
J. Sieper, R. Landewé, M. Rudwaleit, D. van der Heijde, M. Dougados, P. J. Mease, J. Braun, A. Deodhar, A. Kivitz, J. Walsh, B. Hoepken, T. Nurminen & W. P. Maksymowych. (2015) Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. Arthritis & Rheumatology 67:3, pages 668-677.
Crossref
Crossref
R.G. Langley & K. Reich. (2013) The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials. British Journal of Dermatology 169:6, pages 1198-1206.
Crossref
Crossref
Kevin A. Hallgren & Katie Witkiewitz. (2013) Missing Data in Alcohol Clinical Trials: A Comparison of Methods. Alcoholism: Clinical and Experimental Research 37:12, pages 2152-2160.
Crossref
Crossref
Michael A. McIsaac, Richard J. Cook & Melanie Poulin-Costello. (2013) Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. Dermatology 226:1, pages 19-27.
Crossref
Crossref
Wolf-Henning Boehncke. (2011) Clinical long-term studies: data collection and assessment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:6, pages 479-485.
Crossref
Crossref